Hikma's announcement ties into that sentiment, coming with the strap line: "America Leans on Hikma: Quality Medicines ...

Galapagos announces leadership transition. European biotechnology company Galapagos completed a significant leadership ...

GRIN-related neurodevelopmental disorder (GRIN-NDD) is a family of rare, genetically defined neurodevelopmental disorders ...

In the case of the amyloid drugs, Eisai Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab) – there are also ...

BioCryst has agreed to sell its European business based on hereditary angioedema (HAE) therapy Orladeyo to Italy's Neopharmed ...

It's a shot in the arm for Cambridge, Massachusetts-based Moderna as it faces an evolving regulatory environment for vaccines ...

Since the first-generation CAR-Ts reached the market several years ago, clinicians have become more adept at handling ...

ASCO 2025 spotlighted new data across haematologic cancers this year. To discuss announcements in liquid cancers further, as opposed to solid tumours, pharmaphorum spoke with Dr Lore Gruenbaum, chief ...

At Axtria Ignite 2025 in Princeton, New Jersey, web editor Nicole Raleigh spoke with the company’s co-founder, president, and CEO Jaswinder Chadha. An AI-first data analytics innovator focused on ...

The UK is studying cases of pancreatitis in people taking drugs based on GLP-1 receptor agonists for weight loss or type 2 ...

Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

At Longeveron, Dr. Joshua Hare and his team are working on an Alzheimer’s treatment using human-derived bone marrow ...